Paul Tudor Jones Verona Pharma PLC Transaction History
Tudor Investment Corp Et Al
- $29 Billion
- Q1 2025
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Verona Pharma PLC stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 88,324 shares of VRNA stock, worth $7.17 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
88,324
Previous 7,200
1126.72%
Holding current value
$7.17 Million
Previous $334,000
1578.74%
% of portfolio
0.02%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding VRNA
# of Institutions
291Shares Held
74.3MCall Options Held
933KPut Options Held
1.98M-
Perceptive Advisors LLC New York, NY6.56MShares$533 Million17.44% of portfolio
-
Janus Henderson Group PLC London, X05.52MShares$448 Million0.2% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y93.92MShares$319 Million17.31% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.46MShares$281 Million13.82% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.89MShares$235 Million3.9% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $4.95B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...